BioNTech revenue and financials
$97.64Change from previous close: +0.76%Absolute change: +$0.74
In the fiscal year ended December 2025, BioNTech reported revenue of €2.87B (+4.32% year over year). The net loss was €1.14B.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +4.32%
- 2025 vs 2024
- Net margin
- -39.6%
- 2024: -24.2%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total revenue | 106 | 118 | 907 | 1,519 | 261 | — |
| Cost of revenue | 97.0 | 71.4 | 333 | 148 | 76.4 | — |
| Gross profit | 8.6 | 46.7 | 574 | 1,371 | 184 | — |
| Selling, general and administrative | 198 | 164 | 292 | 149 | 137 | — |
| Research and development | 551 | 557 | 505 | 565 | 509 | — |
| Operating income | -939 | -671 | -281 | 654 | -472 | — |
| EBIT | -855 | -564 | -676 | 654 | -399 | — |
| EBITDA | -589 | -443 | -512 | 778 | -348 | — |
| Interest expense | 3.5 | 4.0 | — | — | 3.7 | 33.9 |
| Pre-tax income | -859 | -568 | -227 | 24.7 | -403 | — |
| Income tax | -37.9 | -36.2 | 77.6 | 53.4 | -16.1 | — |
| Net income | -821 | -532 | -305 | -28.7 | -387 | — |
| Net income to common shareholders | -821 | -532 | -305 | -28.7 | -387 | — |
| Basic EPS | -3.24 | -2.10 | -1.25 | -0.12 | -1.60 | — |
| Diluted EPS | -3.24 | -2.10 | -1.25 | -0.12 | -1.60 | — |
| Average shares (basic) | 253 | 253 | 244 | 239 | 242 | — |
| Average shares (diluted) | 253 | 253 | 244 | 239 | 242 | — |